看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。: [. J/ ?+ Q) V: O4 d) m! _) y. f
/ X- @+ e; n) T/ L! I7 R& Q4 }; z6 g
. H* J2 H$ H- I: r0 xCurrently available feasibility data for possible combination strategies. $ {- y0 j4 p" g( [! d/ Q* g
————————————————————————————————2 Y& X0 ^& S' `
Combination Feasibility according to preliminary data + u6 _7 J- o/ R( [( X- S V
——————————————————————————————————3 p# G+ M4 K: B' B8 Q6 F/ q
Bevacizumab + sorafenib Yes, reduced dose 8 P+ W# e% N1 _3 C
Bevacizumab + sunitinib† No 6 v+ [; w' a* H" ]2 B9 c
Bevacizumab + temsirolimus Yes
, w3 T G4 o xBevacizumab + everolimus Yes
6 H8 K3 A4 @% X$ P5 }3 ?Sorafenib + sunitinib ?
& I, v9 M! J6 S* }Sorafenib + temsirolimus Yes, reduced dose 0 s/ @( |- L/ a' d2 i- o: K& j
Sorafenib + everolimus Yes, reduced dose
/ C4 `7 x0 L5 ~8 R5 d2 w0 f" u: HSunitinib + temsirolimus† No ' Y, d, _9 W: m6 A; j; \/ b" F
Sunitinib + everolimus ? 2 y4 O. V" V0 I A' m+ c7 p; v' y# \& d
Temsirolimus + everolimus ?
# n& p( r$ _) Q: T————————————————————: w3 p! d# m; v6 J& D$ B
†Led to US FDA warning.) T& l: Q6 B. r7 }1 S1 P- f6 o
?: As yet unattempted combination.$ v8 s- ]! b) }7 u
|